<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190615</url>
  </required_header>
  <id_info>
    <org_study_id>NICDOS1TEMCP</org_study_id>
    <nct_id>NCT04190615</nct_id>
  </id_info>
  <brief_title>Determination of ClotPro Paediatric Reference Range Study</brief_title>
  <official_title>Determination of Reference Ranges of Thromboelastometry ClotPro Analyser in Paediatric Patients Undergoing Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Children's Diseases, Slovakia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Children's Diseases, Slovakia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) with improved
      technology was developed. This device has an improved new-generation viscoelastometric
      testing technique and enables the detection and assessment of factor deficiencies, low
      fibrinogen, platelet contribution (to whole blood coagulation), heparin and direct oral
      anticoagulants effects, fibrinolysis and antifibrinolytic drugs. This study aims to determine
      reference ranges for the ClotPro device for all paediatric age groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Viscoelastic testing as a relatively novel method to assess coagulation status appears
      favourable in reducing blood product transfusions. The tests are performed on whole blood
      instead of plasma, which saves time and gives a quick sight at the interaction between
      cellular and plasmatic clotting factors.

      Reviews of the literature suggest that transfusions of packed red blood cells (pRBC), plasma,
      and platelets are all decreased in patients whose transfusions were guided by viscoelastic
      tests rather than by clinical judgement or conventional laboratory tests.

      The benefits of viscoelastic coagulation monitoring have been described in many fields of
      surgery and intensive care. Current literature and a guideline for the treatment of massive
      haemorrhage in perioperative bleeding and trauma patients recommend the use of viscoelastic
      tests to guide haemostatic resuscitation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 0 to 3 months for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 0-3months age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 4 to 12 months for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test .</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 4-12months age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 13 to 24 months for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test .</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 13-24months age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 2 to 5 years for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 2-5years age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 6 to10 years for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 6 to10 years group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 11-16 years for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 11-16 years group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age related differences in thromboelastometry parameters</measure>
    <time_frame>12 months</time_frame>
    <description>possible differences in monitored parameters across age groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender-related differences in thromboelastometry parameters</measure>
    <time_frame>12 months</time_frame>
    <description>possible differences in parameters between genders.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Clotting and Bleeding Disorders</condition>
  <condition>Child Development</condition>
  <condition>Infant Development</condition>
  <condition>Coagulopathy</condition>
  <arm_group>
    <arm_group_label>0 to 3 months</arm_group_label>
    <description>0 (term newborns) to 3 month of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 to12 months</arm_group_label>
    <description>infants from 4month to 12month of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13 to 24 months</arm_group_label>
    <description>children from 13month to 2years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 to 5 years</arm_group_label>
    <description>children from 2 to 5 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 to 10 years</arm_group_label>
    <description>children from 2 to 10 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11 to16 years</arm_group_label>
    <description>children from 11 to 16 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>thromboelastometry test (TEM test)</intervention_name>
    <description>TEM test from the whole blood sample</description>
    <arm_group_label>0 to 3 months</arm_group_label>
    <arm_group_label>11 to16 years</arm_group_label>
    <arm_group_label>13 to 24 months</arm_group_label>
    <arm_group_label>2 to 5 years</arm_group_label>
    <arm_group_label>4 to12 months</arm_group_label>
    <arm_group_label>6 to 10 years</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        6 Individual age categories are determined to monitor: ASA physical status I-II

          1. 0 (full term) to 3 months

          2. 4 to12 months

          3. 13 to 24 months

          4. 2 to 5 years

          5. 6 to10 years

          6. 11 to 16 years Demographic data to be recorded: age, gender, weight, height.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  paediatric patients attending hospital for elective surgery or diagnostic imaging
             undergoing general anaesthesia are going to be eligible to participate.

          -  children whose parents agree to participate are provided with oral and written
             information and written informed consent has to be obtained.

        Exclusion Criteria:

          -  problematic blood collection

          -  age over 16 years

          -  emergency surgery

          -  systemic infection

          -  known bleeding disorders

          -  history of congenital or acquired coagulopathy including renal, liver and bone marrow
             disease,

          -  any medication interfering with haemostasis

          -  prophylactic or therapeutic anticoagulant therapy (acetylsalicylic acid within the
             last 10 days or low-molecular-weight heparins within the last 48 h)

          -  administration of colloids hydroxyethyl starch (HES)/albumin, or blood products before
             the blood withdrawal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Laukova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Childrenʼs Diseases, Bratislava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivana Lisačkova</last_name>
    <phone>00421259371333</phone>
    <email>ivana.lisackova@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katarina Laukova, MD</last_name>
    <email>katya.lauko@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Childrenʼs Diseases, Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katarina Laukova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Children's Diseases, Slovakia</investigator_affiliation>
    <investigator_full_name>Katarina Laukova, MD</investigator_full_name>
    <investigator_title>Paediatric Anaesthetist, Attending physician</investigator_title>
  </responsible_party>
  <keyword>thromboelastometry</keyword>
  <keyword>viscoelastic testing</keyword>
  <keyword>reference ranges</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

